Loading
A phase 2 trial of fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Sun Yat-sen University, now recruiting.
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients is a phase 2, interventional study registered as NCT04084496 by Sun Yat-sen University, with a registry enrolment figure of 80 participants, started 2019-09-01 and due to reach its primary completion in 2024-12-31. Interventions recorded: Folfirinox. Conditions listed: Pancreatic Cancer. Primary outcome: Disease free survival. Pancreatic eligibility wording from the registry: "* Histologically confirmed adenocarcinoma of the pancreas without distant metastases". Sites: China. No results are recorded here; the registry entry is the source.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.